1. Home
  2. OFLX vs CBIO Comparison

OFLX vs CBIO Comparison

Compare OFLX & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omega Flex Inc.

OFLX

Omega Flex Inc.

HOLD

Current Price

$28.99

Market Cap

333.0M

Sector

Industrials

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$10.28

Market Cap

340.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
OFLX
CBIO
Founded
1975
2003
Country
United States
United States
Employees
N/A
44
Industry
Industrial Specialties
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
333.0M
340.4M
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
OFLX
CBIO
Price
$28.99
$10.28
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$26.67
AVG Volume (30 Days)
37.1K
147.9K
Earning Date
06-12-2026
01-01-0001
Dividend Yield
4.73%
N/A
EPS Growth
N/A
N/A
EPS
1.47
N/A
Revenue
$98,296,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.58
$8.72
52 Week High
$39.98
$17.39

Technical Indicators

Market Signals
Indicator
OFLX
CBIO
Relative Strength Index (RSI) 30.83 40.20
Support Level $26.50 $8.72
Resistance Level $29.54 $13.36
Average True Range (ATR) 1.76 0.85
MACD -0.59 -0.14
Stochastic Oscillator 16.07 8.21

Price Performance

Historical Comparison
OFLX
CBIO

About OFLX Omega Flex Inc.

Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States. The company derives revenues from the manufacture and sale of flexible metal hose and accessories.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: